Enhancing Doxorubicin Sensitivity in Osteosarcoma Cancer Cells:
                    Unveiling the Role of Resveratrol-Induced Oxidative DNA Damage

Mohammad Reza Bazavar; Hamed Helali; Linda Mohammadzadeh Boukani; Bahman Yousefi; Amir Valizadeh

doi:10.1055/a-2567-9916

Drug Research, Table of Contents

Drug Res (Stuttg) 2025; 75(06): 202-208
DOI: 10.1055/a-2567-9916

Original Article

Enhancing Doxorubicin Sensitivity in Osteosarcoma Cancer Cells: Unveiling the Role of Resveratrol-Induced Oxidative DNA Damage

Authors

Mohammad Reza Bazavar

¹Department of Orthopedic Surgery, School of Medicine and Shohada Educational Hospital, Tabriz University of Medical Sciences, Tabriz, Iran
Hamed Helali

¹Department of Orthopedic Surgery, School of Medicine and Shohada Educational Hospital, Tabriz University of Medical Sciences, Tabriz, Iran
Linda Mohammadzadeh Boukani

²Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
Bahman Yousefi

²Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran

³Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
Amir Valizadeh

²Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran

³Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

Abstract

Introduction

Our current research aims to investigate how Resveratrol influences DOX-induced apoptosis in Saos-2 cells resulting from DNA damage.

Methods

Saos-2 cells were cultured with DOX, and an MTT assay was conducted to evaluate cell viability. The expression levels of DNA damage markers were evaluated using qRT-PCR and western blotting methods. Apoptosis was also investigated by flow cytometry.

Results

In a dose-dependent way, DOX produced a profuse suppression of cell proliferation. This study investigates the effect of Resveratrol on DOX-induced apoptosis due to DNA damage in Saos-2 cells (P<0.05). There was an increase in H2AX, ATR, ATM, Rad51, and p53 expression, possibly contributing to subsequent apoptosis. Furthermore, Resv enhanced the apoptosis caused by DOX in Saos-2 cells.

Conclusion

The findings from the current research provide an understanding of how Resv plays a role in potentially treating osteosarcoma by enhancing DOX-induced apoptosis.

Keywords

pharmacology - drug research - chemical biology

Full Text

References

References
1 Gill J, Gorlick R. Advancing therapy for osteosarcoma. Nat Rev Clin Oncol 2021; 18: 609-624
2 Eaton BR, Schwarz R, Vatner R. et al. Osteosarcoma. Pediatr Blood Cancer 2021; 68: e28352
3 Wu C, Gong S, Duan Y. et al. A tumor microenvironment-based prognostic index for osteosarcoma. J Biomed Sci 2023; 30: 23
4 Meltzer PS, Helman LJ. New Horizons in the Treatment of Osteosarcoma. N Engl J Med 2021; 385: 2066-2076
5 Abdelrahman S, Ireland A, Winter EM. et al. Osteoporosis after spinal cord injury: aetiology, effects and therapeutic approaches. J Musculoskelet Neuronal Interact 2021; 21: 26-50
6 Bukowski K, Kciuk M, Kontek R. Mechanisms of Multidrug Resistance in Cancer Chemotherapy. Int J Mol Sci 2020; 21: 9
7 Wei G, Wang Y, Yang G. et al. Recent progress in nanomedicine for enhanced cancer chemotherapy. Theranostics. 2021; 11: 6370-6392
8 Makovec T. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiol Oncol 2019; 53: 148-158
9 Behranvand N, Nasri F, Zolfaghari Emameh R. et al. Chemotherapy: a double-edged sword in cancer treatment. Cancer Immunol Immunother 2022; 71: 507-526
10 Benjamin RS. Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma: A Historical Perspective. Adv Exp Med Biol 2020; 1257: 1-10
11 Kciuk M, Gielecińska A, Mujwar S. et al. Doxorubicin-An Agent with Multiple Mechanisms of Anticancer Activity. Cells 2023; 12: 4
12 Mattioli R, Ilari A, Colotti B. et al. Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming. Molecular Aspects of Medicine 2023; 93: 101205
13 Kursvietiene L, Kopustinskiene DM, Staneviciene I. et al Anti-Cancer Properties of Resveratrol: A Focus on Its Impact on Mitochondrial Functions. Antioxidants (Basel) 2023; 12 12
14 Han Y, Jo H, Cho JH. et al. Resveratrol as a Tumor-Suppressive Nutraceutical Modulating Tumor Microenvironment and Malignant Behaviors of Cancer. Int J Mol Sci 2019; 20: 4
15 Ko JH, Sethi G, Um JY. et al. The Role of Resveratrol in Cancer Therapy. Int J Mol Sci 2017; 18: 12
16 Roshani M, Jafari A, Loghman A. et al. Applications of resveratrol in the treatment of gastrointestinal cancer. Biomed Pharmacother 2022; 153: 113274
17 Holohan C, Van Schaeybroeck S, Longley DB. et al. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013; 13: 714-726
18 Perrone D, Fuggetta MP, Ardito F. et al. Resveratrol (3,5,4'-trihydroxystilbene) and its properties in oral diseases. Exp Ther Med 2017; 14: 3-9
19 Fabre KM, Saito K, DeGraff W. et al. The effects of resveratrol and selected metabolites on the radiation and antioxidant response. Cancer Biol Ther 2011; 12: 915-923
20 Choi CY, Lim SC, Lee TB. et al. Molecular Basis of Resveratrol-Induced Resensitization of Acquired Drug-Resistant Cancer Cells. Nutrients 2022; 14: 3
21 Gupta SC, Kannappan R, Reuter S. et al. Chemosensitization of tumors by resveratrol. Ann N Y Acad Sci 2011; 1215: 150-160
22 Tiek D, Cheng SY. DNA damage and metabolic mechanisms of cancer drug resistance. Cancer Drug Resist 2022; 5: 368-379
23 Kim TH, Shin YJ, Won AJ. et al. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. Biochim Biophys Acta 2014; 1840: 615-625
24 Brockmueller A, Sajeev A, Koklesova L. et al. Resveratrol as sensitizer in colorectal cancer plasticity. Cancer Metastasis Rev 2023; 43: 55-85
25 Leon-Galicia I, Diaz-Chavez J, Albino-Sanchez ME. et al. Resveratrol decreases Rad51 expression and sensitizes cisplatin‑resistant MCF‑7 breast cancer cells. Oncol Rep 2018; 39: 3025-3033